We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+33.14%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$485M
AUM Growth
+$61.9M
Cap. Flow
-$37.6M
Cap. Flow %
-7.74%
Top 10 Hldgs %
86.84%
Holding
22
New
–
Increased
3
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$2.95M
2
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$2.47M
3
VRAY
ViewRay, Inc.
VRAY
+$72.3K

Top Sells

Rank Stock Value
1
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$17.9M
2
CTLT
CATALENT, INC.
CTLT
+$10.9M
3
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$5.08M
4
XENT
Intersect ENT, Inc
XENT
+$3.03M
5
DERM
Dermira, Inc.
DERM
+$3M

Sector Composition

Rank Sector Weight
1 Healthcare 65.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$105M 21.73%
4,028,920
– –
ZLTQ
2
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$63.1M 13.01%
1,609,727
-500,000
-24% -$17.9M
CYNA
3
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$45.1M 9.29%
1,121,381
+100,000
+10% +$2.47M
AIMT
4
DELISTED
Aimmune Therapeutics
AIMT
$44.9M 9.24%
2,990,000
– –
VRAY
5
DELISTED
ViewRay, Inc.
VRAY
$33.8M 6.97%
7,480,887
+18,964
+0.3% +$72.3K
ARAV
6
DELISTED
Aravive, Inc. Common Stock
ARAV
$30.9M 6.37%
420,744
+40,816
+11% +$2.95M
CEMP
7
DELISTED
Cempra, Inc.
CEMP
$28.9M 5.95%
1,193,060
– –
ADMA icon
8
ADMA Biologics
ADMA
$2.03B
$26.2M 5.39%
3,608,171
– –
ESPR
9
DELISTED
Esperion Therapeutics
ESPR
$22.7M 4.67%
1,637,125
– –
TTOO
10
DELISTED
T2 Biosystems, Inc
TTOO
$20.5M 4.22%
566
– –
AGRX
11
DELISTED
Agile Therapeutics
AGRX
$15.9M 3.27%
1,138
-154
-12% -$2.2M
ASXC
12
DELISTED
Asensus Surgical, Inc.
ASXC
$14.1M 2.9%
641,217
– –
CDTX
13
DELISTED
Cidara Therapeutics
CDTX
$11.7M 2.41%
51,057
– –
SYRS
14
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.05M 1.45%
50,857
-40,000
-44% -$5.08M
PRTK
15
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$6.28M 1.29%
482,680
– –
XENT
16
DELISTED
Intersect ENT, Inc
XENT
$3.94M 0.81%
248,498
-201,502
-45% -$3.03M
CMRX
17
DELISTED
Chimerix, Inc.
CMRX
$2.62M 0.54%
472,943
– –
PTX
18
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$1.25M 0.26%
201,000
– –
EVAR
19
DELISTED
Lombard Medical, Inc.
EVAR
$417K 0.09%
443,182
-443,181
-50% -$470K
CTLT
20
DELISTED
CATALENT, INC.
CTLT
– –
-472,781
Closed -$10.9M
DERM
21
DELISTED
Dermira, Inc.
DERM
– –
-102,593
Closed -$3M

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Aisling Capital held 22 positions worth $485M, up 15% from $423M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Aisling Capital withdrew a net $37.6M in Q3 2016, closing 2 positions and reducing 5 holdings. Its most notable exit was CATALENT, INC., an estimated $10.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 69% a quarter earlier.

Against the trend, Aisling Capital added an estimated $2.95M to Aravive, Inc. Common Stock.

  • Aisling Capital added most to Aravive, Inc. Common Stock in Q3 2016, an estimated $2.95M increase.
  • Aisling Capital's biggest Q3 2016 reduction was ZELTIQ Aesthetics, Inc., cutting an estimated $17.9M.
  • Aisling Capital fully exited CATALENT, INC. in Q3 2016, selling an estimated $10.9M.
  • Aisling Capital's ten largest holdings make up 87% of its $485M portfolio in Q3 2016.
  • Aisling Capital opened 0 new positions and closed 2 in Q3 2016.
  • Aisling Capital's portfolio value rose 15% quarter-over-quarter to $485M.

Based on Aisling Capital's 13F filing for Q3 2016, filed 10 Nov 2016.